Skip to main content

JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients

International Journal of Hematology volume 97, pages 409–413 (2013)Cite this article

Abstract

Myeloproliferative neoplasms (MPNs) constitute a group of phenotypically diverse chronic myeloid malignancies, characterized by clonal hematopoiesis and excessive production of terminally differentiated myeloid blood cells. The MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), most of which are characterized by a somatic point mutation, V617F, in the janus kinase 2 (JAK2) gene. This mutation was recently shown to occur more frequently in a specific JAK2 haplotype, JAK2 46/1, in North American and European MPN patients. Little is known, however, about JAK2 haplotypes in Japanese MPN patients. Therefore, we examined 108 Japanese patients with MPN, including 19 with PV, 61 with ET, 10 with PMF, and 17 with unclassifiable MPN, as well as 104 control individuals for the JAK2 rs10974944(C/G) single nucleotide polymorphism, in which the G allele indicates the 46/1 haplotype. We found that the JAK2 46/1 haplotype was significantly more frequent in patients with V617F-positive MPN than in controls (odds ratio [OR], 3.6; 95 % confidence interval [CI], 2.2–5.8, p < 0.001), and in PV patients than in controls (OR, 6.3; 95 % CI, 3.0–29.4, p < 0.001). In conclusion, we demonstrated that the JAK2 46/1 haplotype is associated with JAK2 V617F-positive MPNs in Japanese patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.

    PubMed  Article  CAS  Google Scholar 

  2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

    PubMed  CAS  Google Scholar 

  3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.

    PubMed  Article  CAS  Google Scholar 

  4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

    PubMed  Article  CAS  Google Scholar 

  5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.

    PubMed  Article  CAS  Google Scholar 

  6. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115:3842–7.

    PubMed  Article  CAS  Google Scholar 

  7. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41:446–9.

    PubMed  Article  CAS  Google Scholar 

  8. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41:455–9.

    PubMed  Article  CAS  Google Scholar 

  9. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41:450–4.

    PubMed  Article  CAS  Google Scholar 

  10. Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, et al. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol. 2010;89:979–83.

    PubMed  Article  CAS  Google Scholar 

  11. Zhang X, Hu T, Wu Z, Kang Z, Liu W, Guan M. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. Int J Hematol. 2012;96:611–6.

    PubMed  Article  Google Scholar 

  12. Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Med Genet. 2012;13:6.

    PubMed  Article  CAS  Google Scholar 

  13. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24:110–4.

    PubMed  Article  CAS  Google Scholar 

  14. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24:105–9.

    PubMed  Article  CAS  Google Scholar 

  15. Alvarez-Larran A, Angona A, Martinez-Aviles L, Bellosillo B, Besses C. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms. Leuk Res. 2012;36:324–6.

    PubMed  Article  CAS  Google Scholar 

  16. Nahajevszky S, Andrikovics H, Batai A, Adam E, Bors A, Csomor J, et al. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica. 2011;96:1613–8.

    PubMed  Article  CAS  Google Scholar 

  17. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–62.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Drs. Takayuki Tominaga, Toshihiko Ando, Koji Yamashita, and Masatoshi Tsuru for the patient enrollment.

Conflict of interest

None.

Author information

Affiliations

  1. Department of Bio-Signal Analysis, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan

    Mayumi Tanaka, Toshiaki Yujiri, Shunsuke Ito & Yukio Tanizawa

  2. Department of Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

    Naoko Okayama & Yuji Hinoda

  3. Department of Hematology, Yamaguchi Grand Medical Center, Yamaguchi, Japan

    Toru Takahashi

  4. Department of Medicine, Towa Municipal Hospital, Yamaguchi, Japan

    Kenji Shinohara

  5. Department of Medicine, Yamaguchi Rosai Hospital, Yamaguchi, Japan

    Yoichi Azuno

  6. Department of Medicine, Shimonoseki Kousei Hospital, Yamaguchi, Japan

    Ryouhei Nawata

Authors
  1. Mayumi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiaki Yujiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shunsuke Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoko Okayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toru Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoichi Azuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryouhei Nawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuji Hinoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yukio Tanizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiaki Yujiri.

About this article

Cite this article

Tanaka, M., Yujiri, T., Ito, S. et al. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients. Int J Hematol 97, 409–413 (2013). https://doi.org/10.1007/s12185-013-1295-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-013-1295-y

Keywords

  • Myeloproliferative neoplasms
  • JAK2
  • Haplotype